SEC Form 6-K filed by Telix Pharmaceuticals Limited
$TLX
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2026
Commission File Number: 001-42128
Telix Pharmaceuticals Limited
(Translation of registrant’s name into English)
55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-
F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On February 20, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited (the “Company”) filed the following
announcements with the Australian Securities Exchange: (i) Appendix 4E and 2025 Annual Report, (ii) Appendix
4G and 2025 Corporate Governance Statement, (iii) 2025 Full Year Results Announcement, and (iv) 2025 Full Year
Results Presentation, which are attached to this Form 6-K as Exhibits 99.1, 99.2, 99.3 and 99.4, respectively.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Telix Pharmaceuticals Limited | ||
Date: February 19, 2026 | By: | /s/ Genevieve Ryan |
Name: Genevieve Ryan | ||
Title: Company Secretary | ||